0001213900-22-063616.txt : 20221012 0001213900-22-063616.hdr.sgml : 20221012 20221012201534 ACCESSION NUMBER: 0001213900-22-063616 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221011 FILED AS OF DATE: 20221012 DATE AS OF CHANGE: 20221012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schneiderman Daniel H CENTRAL INDEX KEY: 0001565536 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40804 FILM NUMBER: 221307850 MAIL ADDRESS: STREET 1: 760 PARKSIDE AVE. SUITE 304 STREET 2: SUITE 207 CITY: BROOKLYN STATE: NY ZIP: 11226 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pasithea Therapeutics Corp. CENTRAL INDEX KEY: 0001841330 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851591963 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2110 NARCISSUS CT CITY: VENICE STATE: CA ZIP: 90291 BUSINESS PHONE: 8184226172 MAIL ADDRESS: STREET 1: 2110 NARCISSUS CT CITY: VENICE STATE: CA ZIP: 90291 4 1 ownership.xml X0306 4 2022-10-11 0 0001841330 Pasithea Therapeutics Corp. KTTA 0001565536 Schneiderman Daniel H 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139 0 1 0 0 Chief Financial Officer Stock Option (to acquire Common Stock) 1.26 2022-10-11 4 A 0 300000 0 A 2023-10-11 2032-10-11 Common Stock 300000 300000 D The Reporting Person was granted 300,000 stock options. The stock options have a ten-year term and vest over three years, subject to Mr. Schneiderman remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches monthly for two years thereinafter. /s/ Daniel Schneiderman 2022-10-12